» Articles » PMID: 37614947

Indicators of Clinical Performance in Monitoring Soft Tissue Sarcoma Management: a Population-based Perspective

Abstract

Background: Soft tissue sarcomas (STS) are rare malignancies which prognosis varies significantly by primary site, histological subtype, and tumor stage. Their low incidence, and the complexity of their clinico-pathological characteristics demand standardized, cancer-tailored diagnostics and therapies managed at high-volume, multidisciplinary care centers. This study evaluates the quality of STS management in north-east Italy (Veneto Region) through a list of defined clinical indicators.

Methods: This population-based study concerns all incident cases of STS in 2018 (214 cases) recorded in the adult population censored by the Veneto's regional Cancer Registry. Based on the international literature, a multidisciplinary working group of experts identified a set of indicators for monitoring the quality of diagnostic, therapeutic, and end-of-life clinical interventions. The quality of care was assessed by comparing the reference thresholds with the indicators' values achieved in clinical practice.

Results: Diagnostic procedures showed poor adherence to the thresholds, with a low percentage of histological diagnoses validated by a second opinion. The indicators relating to the surgical treatment of superficial, small, low-grade STS, or of medium, high-grade STS of the head-neck, trunk, or limbs were consistent with the thresholds, while for intermediate, high-grade (large-sized, deep) and retroperitoneal STS they fell significantly below the thresholds.

Conclusion: A critical evaluation of the clinical indicators allowed to uncover the procedures needing corrective action. Monitoring clinical care indicators improves cancer care, confirms the importance of managing rare cancers at highly specialized, high-volume centers, and promotes the ethical sustainability of the healthcare system.

Citing Articles

Surgical resection due to poor outcome of the immunotherapy of a relapsed mediastinal liposarcoma: a case report.

Wang M, Xu S, Wu L, Li Z, Xie D Future Sci OA. 2024; 10(1):FSO906.

PMID: 38827794 PMC: 11140642. DOI: 10.2144/fsoa-2023-0099.

References
1.
Styring E, Billing V, Hartman L, Nilbert M, Seinen J, Veurink N . Simple guidelines for efficient referral of soft-tissue sarcomas: a population-based evaluation of adherence to guidelines and referral patterns. J Bone Joint Surg Am. 2012; 94(14):1291-6. DOI: 10.2106/JBJS.K.01271. View

2.
Choi J, Ro J . The 2020 WHO Classification of Tumors of Soft Tissue: Selected Changes and New Entities. Adv Anat Pathol. 2020; 28(1):44-58. DOI: 10.1097/PAP.0000000000000284. View

3.
Bovero A, Opezzo M, Botto R, Gottardo F, Torta R . Hope in end-of-life cancer patients: A cross-sectional analysis. Palliat Support Care. 2021; 19(5):563-569. DOI: 10.1017/S1478951520001388. View

4.
Villano A, Zeymo A, Nigam A, Chan K, Shara N, Unger K . Radical excision for retroperitoneal soft tissue sarcoma: A national propensity-matched outcomes analysis. Surgery. 2020; 168(5):831-837. DOI: 10.1016/j.surg.2020.05.031. View

5.
Mathoulin-Pelissier S, Chevreau C, Bellera C, Bauvin E, Saves M, Grosclaude P . Adherence to consensus-based diagnosis and treatment guidelines in adult soft-tissue sarcoma patients: a French prospective population-based study. Ann Oncol. 2013; 25(1):225-31. PMC: 3868321. DOI: 10.1093/annonc/mdt407. View